5HT2AHemmung

5HT2AHemmung, or inhibition of the serotonin 5-HT2A receptor, refers to reducing the signaling mediated by this receptor. The 5-HT2A receptor is a G protein–coupled receptor that participates in various central nervous system processes, including perception, cognition and mood. Inhibition can be achieved by antagonists that block receptor activation or by inverse agonists that lower the receptor’s baseline activity. In pharmacology, 5HT2AHemmung is a common mechanism underlying several drug classes, especially atypical antipsychotics.

Mechanism and effects: Antagonists prevent 5-HT2A activation by serotonin or other ligands, dampening downstream Gq/11 signaling and related pathways. This modulation can influence cortical glutamatergic transmission and dopaminergic activity in the prefrontal cortex, contributing to antipsychotic efficacy and a reduced risk of extrapyramidal symptoms compared with pure D2 antagonists. Inhibition of 5-HT2A signaling also counteracts certain effects produced by 5-HT2A agonists, such as psychedelics, which is relevant in research and clinical contexts.

Clinical relevance and examples: Many second-generation (atypical) antipsychotics exhibit substantial 5-HT2A antagonism, including clozapine, olanzapine, risperidone, ziprasidone and lurasidone. Some antidepressants and multimodal agents, such as mirtazapine, also act as 5-HT2A antagonists. Ketanserin and related compounds are more selective 5-HT2A antagonists used mainly in research or specific clinical contexts.

Safety and considerations: 5-HT2A inhibition can be associated with sedation, weight gain and orthostatic effects, among other properties linked to broader pharmacological profiles. The overall therapeutic impact depends on the balance with other receptor interactions in the same drug.